Navigation Links
AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
Date:1/18/2010

LONDON and GLOSTRUP, Denmark, Jan. 18 /PRNewswire-FirstCall/ -- AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100118/PH38535LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

Under the agreement, the companies will work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The financial terms of the deal were not disclosed.

The collaboration will leverage Dako's position as a leader in cancer diagnostics and a strong partner in the development of diagnostic tests used in conjunction with drug therapies. AstraZeneca will bring its extensive experience in the development and commercialization of vital oncology products worldwide.

"We believe it is important for pharmaceutical and diagnostic companies to combine their expertise in a strong collaborative approach to enable the development of diagnostic tests for use with drug therapies. Targeted treatment with personalized medicine is the future, and the outcome of this collaboration will be beneficial not only for cancer patients, but is also a significant contributive factor in cutting health care costs," says Lars Holmkvist, CEO of Dako Denmark A/S.

Alan Barge, Head of Oncology Development at AstraZeneca said: "This agreement, under the umbrella of AstraZeneca's Personalised Healthcare strategy, will enable us to develop novel, reimbursable products that can improve patients' lives. The alliance heralds the intentions of both companies to work closely together to develop new drugs linked to diagnostic tests that predict which patients are most likely to respond to treatment, ensuring that we are giving the right treatment, to the right patient, the first time."

Ruth March, Personalised Healthcare Leader at AstraZeneca, said: "This agreement is the first in a series of strategic alliances with diagnostic companies that will enable AstraZeneca to achieve our Personalised Healthcare aims and better serve patient health." 

For AstraZeneca, today's announcement marks the continuation of their commitment to Personalised Healthcare as demonstrated by the launch of IRESSA in the EU for patients with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase).

The agreement advances Dako's ongoing strategy to collaborate with strong partners in the pharmaceutical sector to enhance the offering of Dako's companion diagnostic assays.

About Dako

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako covers essentially all of the global anatomic pathology markets. Dako is owned by a private equity fund, EQT. www.dako.com

About AstraZeneca

AstraZeneca (NYSE: AZN)  is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world´s leading pharmaceutical companies with healthcare sales of US$31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

SOURCE AstraZeneca

RELATED LINKS
http://www.astrazeneca-us.com
AP Archive: http://photoarchive.ap.org

'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
2. Novexel to be Acquired by AstraZeneca
3. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
4. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
5. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
6. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
7. Jubilant Enters Research Collaboration With AstraZeneca
8. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
9. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
10. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
11. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
Breaking Medicine Technology:
(Date:6/26/2017)... TX (PRWEB) , ... June 26, 2017 , ... ... their coding staff, and consumers are seeing lots of red these days. According ... contain inaccurate charges that result from medical coding errors(1). Some studies point to ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... New patients ... from Dr. Angela Cotey, with or without a referral. Dr. Cotey is a trusted ... of this preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, ...
(Date:6/25/2017)... Aliso Viejo, CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric ... place presets above footage and sound in the timeline and write in the lyrics to ... screen before flying back out. Each line of the text can be added modularly for ...
(Date:6/25/2017)... ... , ... An increase in wetter weather in the Northern California area naturally ... a humdinger of an allergy season. A relief from drought conditions is most welcome, ... and weed pollen. , “Our patients have been reporting the typical allergy season ...
(Date:6/25/2017)... ... June 25, 2017 , ... With a heatwave currently bearing down on Northern California ... at the pool. Being swimsuit ready is easy with laser hair removal. , The ... can be a burdensome routine when all you want to do is get out, dive ...
Breaking Medicine News(10 mins):